MADISON – Company working on a prostate cancer vaccine receives funding

    Madison Vaccines Incorporated said Monday the company has closed on $8 million in financing to move forward with its therapies for prostate cancer.

     
    MVI is working on two vaccines to combat prostate cancer, one of which is in Phase 2 clinical trials. The technology was developed in the lab of UW-Madison medical school professor Douglas McNeel.

    Read more.

    Sign up for BizTimes Daily Alerts

    Stay up-to-date on the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin

    No posts to display